CN112040945A - 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途 - Google Patents

葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途 Download PDF

Info

Publication number
CN112040945A
CN112040945A CN201980028636.8A CN201980028636A CN112040945A CN 112040945 A CN112040945 A CN 112040945A CN 201980028636 A CN201980028636 A CN 201980028636A CN 112040945 A CN112040945 A CN 112040945A
Authority
CN
China
Prior art keywords
insulin
subject
liver
combination
units
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980028636.8A
Other languages
English (en)
Chinese (zh)
Inventor
J.L.R.弗里曼
M.C.瓦尔卡塞洛佩兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
vTv Therapeutics LLC
Original Assignee
vTv Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by vTv Therapeutics LLC filed Critical vTv Therapeutics LLC
Priority to CN202511876733.6A priority Critical patent/CN121371187A/zh
Priority to CN202510257535.5A priority patent/CN120131969A/zh
Publication of CN112040945A publication Critical patent/CN112040945A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980028636.8A 2018-06-12 2019-06-10 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途 Pending CN112040945A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202511876733.6A CN121371187A (zh) 2018-06-12 2019-06-10 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途
CN202510257535.5A CN120131969A (zh) 2018-06-12 2019-06-10 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862683772P 2018-06-12 2018-06-12
US62/683,772 2018-06-12
US201962857753P 2019-06-05 2019-06-05
US62/857,753 2019-06-05
PCT/US2019/036227 WO2019241089A1 (en) 2018-06-12 2019-06-10 Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202510257535.5A Division CN120131969A (zh) 2018-06-12 2019-06-10 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途
CN202511876733.6A Division CN121371187A (zh) 2018-06-12 2019-06-10 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途

Publications (1)

Publication Number Publication Date
CN112040945A true CN112040945A (zh) 2020-12-04

Family

ID=67297247

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201980028636.8A Pending CN112040945A (zh) 2018-06-12 2019-06-10 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途
CN202510257535.5A Pending CN120131969A (zh) 2018-06-12 2019-06-10 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途
CN202511876733.6A Pending CN121371187A (zh) 2018-06-12 2019-06-10 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202510257535.5A Pending CN120131969A (zh) 2018-06-12 2019-06-10 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途
CN202511876733.6A Pending CN121371187A (zh) 2018-06-12 2019-06-10 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途

Country Status (9)

Country Link
US (4) US10952993B2 (https=)
EP (2) EP3806852A1 (https=)
JP (2) JP2021526130A (https=)
KR (1) KR20210020866A (https=)
CN (3) CN112040945A (https=)
AU (2) AU2019287437A1 (https=)
CA (1) CA3093025A1 (https=)
MX (2) MX2020008905A (https=)
WO (1) WO2019241089A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112040945A (zh) 2018-06-12 2020-12-04 Vtv治疗有限责任公司 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
CA3181722A1 (en) 2020-06-08 2021-12-16 Jing TENG Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104349790A (zh) * 2012-05-17 2015-02-11 转化技术制药有限责任公司 用于治疗糖尿病的葡萄糖激酶活化剂组合物

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB771147A (en) 1954-06-04 1957-03-27 Merck & Co Inc Derivatives of urea
US3152136A (en) 1958-10-30 1964-10-06 Dow Chemical Co Dinitroaroyl-nu-pyridyl amides
US3067250A (en) 1959-01-26 1962-12-04 Dow Chemical Co 4-aryl, 1, 1-di propynyl-semicarbazides
US3317534A (en) 1963-10-30 1967-05-02 Chugai Pharmaceutical Co Ltd Benzamidopyrimidines
US3551442A (en) 1965-04-06 1970-12-29 Pechiney Saint Gobain Thiazole derivatives
US3424762A (en) 1966-03-07 1969-01-28 Robins Co Inc A H Certain 3-ureidopyrrolidines
ZA6706928B (https=) 1967-03-23
CH493195A (de) 1968-01-23 1970-07-15 Ciba Geigy Schädlingsbekämpfungsmittel
US4175081A (en) 1968-02-01 1979-11-20 Mobil Oil Corporation 5-Substituted thiadiazole ureas
GB1195672A (en) 1968-02-01 1970-06-17 Mobil Oil Corp Novel Urea Derivatives and Herbicides containing the same
FR7428M (https=) 1968-05-06 1969-11-12
CH498859A (de) 1968-07-17 1970-11-15 Agripat Sa Verfahren zur Herstellung von Thiadiazolyl-harnstoffen
GB1266769A (https=) 1969-08-15 1972-03-15
BE754783A (fr) 1969-08-15 1971-02-12 May & Baker Ltd Derives thiazolyl a usage herbicide leur preparation et les compositions qui les contiennent
GB1318291A (en) 1970-04-15 1973-05-23 Shell Int Research Carboxamide derivatives and fungicidal compositions containing them
NL7106557A (https=) 1970-06-15 1971-12-17
IT960595B (it) 1971-06-16 1973-11-30 Hispaco Ag Navetta per tessitura
US3887709A (en) 1971-09-16 1975-06-03 Zdzislaw Brzozowski 2-Pyrazoline-1-carboxamide sulfonamide derivatives useful as hypoglycemic agents
US3862163A (en) 1971-10-14 1975-01-21 Schering Ag Phenoxycarboxylic acid amides
DE2151766C3 (de) 1971-10-14 1981-03-19 Schering Ag, 1000 Berlin Und 4619 Bergkamen N-Thiazolinyl-phenoxycarbonsäureamide
US3874873A (en) 1972-03-27 1975-04-01 Fmc Corp Herbicidal compositions based on 1,2,3-thiadiazol-5-yl ureas
IL44058A (en) 1973-02-02 1978-10-31 Ciba Geigy Ag 3amino-1,2,4-benzotriazine 1,4-di-noxide derivatives, their preparation and compositions for the control of microorganisms containing them
AT323195B (de) 1973-03-16 1975-06-25 Hurka Wilhelm Verfahren zur herstellung neuer salze von biguaniden
JPS5614643B2 (https=) 1973-07-02 1981-04-06
FR2243684B1 (https=) 1973-09-19 1977-01-28 Semb
PL106114B1 (pl) 1976-12-31 1979-11-30 Akad Medyczna Sposob wytwarzania nowych n-(4-/2-/pirazolo-1-karbonamido/-etylo/-benzenosulfonylo)-mocznikow
DE2712630A1 (de) 1977-03-23 1978-09-28 Bayer Ag 1,3,4-thiadiazol-2-yl-harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung als fungizide
DE2716324A1 (de) 1977-04-07 1978-10-12 Schering Ag 1,2,3-thiadiazol-3-in-5-yliden- harnstoffe, verfahren zur herstellung dieser verbindungen sowie diese enthaltende mittel mit wachstumsregulatorischer wirkung fuer pflanzen
JPS6033109B2 (ja) 1977-04-28 1985-08-01 塩野義製薬株式会社 尿素誘導体の合成法
US4241072A (en) 1979-01-18 1980-12-23 Merck & Co., Inc. Substituted ureas and processes for their preparation
DE2928485A1 (de) 1979-07-14 1981-01-29 Bayer Ag Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen
IL72093A0 (en) 1983-06-20 1984-10-31 Lilly Co Eli N'-substituted(3-alkyl-5-isothiazolyl)urea derivatives
US4694004A (en) 1984-07-09 1987-09-15 Fujisawa Pharmaceutical Co., Ltd. Semicarbazide derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
US4808722A (en) 1985-10-31 1989-02-28 Fmc Corporation Pyridinylurea N-oxide compounds and agricultural uses
JPS6456660A (en) 1987-05-11 1989-03-03 Sumitomo Chemical Co Urea derivative or its salt, production thereof and germicide for agriculture and horticulture containing said derivative or salt thereof as active ingredient
WO1991004027A1 (en) 1989-09-15 1991-04-04 Pfizer Inc. New n-aryl and n-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat)
IE68593B1 (en) 1989-12-06 1996-06-26 Sanofi Sa Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
RU2021258C1 (ru) 1991-02-28 1994-10-15 Агролинц Агрархемикалиен ГмбХ Способ получения несимметрично дизамещенных мочевин
US5371086A (en) 1991-03-15 1994-12-06 The Green Cross Corporation Aminopyridine compounds
JPH05294935A (ja) 1991-03-15 1993-11-09 Green Cross Corp:The アミノピリジン系化合物
WO1993024458A1 (en) 1992-05-28 1993-12-09 Pfizer Inc. New n-aryl and n-heteroarylurea derivatives as inhibitors of acyl coenzyme a:cholesterol acyl transferase (acat)
WO1994014801A1 (en) 1992-12-29 1994-07-07 Smithkline Beecham Plc Heterocyclic urea derivatives as 5ht2c and 5ht2b antagonists
GB9302275D0 (en) 1993-02-05 1993-03-24 Smithkline Beecham Plc Novel compounds
US5849769A (en) 1994-08-24 1998-12-15 Medivir Ab N-arylalkyl-N-heteroarylurea and guandine compounds and methods of treating HIV infection
US5556969A (en) 1994-12-07 1996-09-17 Merck Sharp & Dohme Ltd. Benzodiazepine derivatives
US6579314B1 (en) 1995-03-10 2003-06-17 C.R. Bard, Inc. Covered stent with encapsulated ends
WO1996040629A1 (en) 1995-06-07 1996-12-19 Sugen, Inc. Tyrphostin-like compounds for the treatment of cell proliferative disorders or cell differentiation disorders
US5846990A (en) 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
JPH09124620A (ja) 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
GB9526560D0 (en) 1995-12-27 1996-02-28 Bayer Ag Use of 2-Amino-Heterocycles
CA2197364A1 (en) 1996-02-15 1997-08-16 Toshikazu Suzuki Phenol compound and process for preparing the same
AU1735497A (en) 1996-02-26 1997-09-10 Sumitomo Pharmaceuticals Company, Limited Sulfonylureidopyrazole derivatives
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
US5846985A (en) 1997-03-05 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
SE9702001D0 (sv) 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
US6268384B1 (en) 1997-08-29 2001-07-31 Vertex Pharmaceuticals Incorporated Compounds possessing neuronal activity
US6225346B1 (en) 1997-10-24 2001-05-01 Sugen, Inc. Tyrphostin like compounds
NZ503491A (en) 1997-11-10 2002-08-28 Bristol Myers Squibb Co 2-substituted amino-1,3-benzothiazole derivatives useful as protein tyrosine kinase inhibitors
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
ES2262248T3 (es) 1997-11-14 2006-11-16 Kowa Company. Ltd. Nuevos compuestos amida y medicamente que los contienen.
SK286213B6 (sk) 1997-12-22 2008-05-06 Bayer Corporation Substituované heterocyklické močoviny, farmaceutický prípravok ich obsahujúci a ich použitie
MXPA00006233A (es) 1997-12-22 2002-09-18 Bayer Ag Inhibicion de la actividad de la cinasa p38 utilizando ureas heterociclicas sustituidas.
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
US6407124B1 (en) 1998-06-18 2002-06-18 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
GB9823873D0 (en) 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
CN1332726A (zh) 1998-11-02 2002-01-23 卫福有限公司 吡咯烷化合物及其药物用途
US6337338B1 (en) 1998-12-15 2002-01-08 Telik, Inc. Heteroaryl-aryl ureas as IGF-1 receptor antagonists
WO2000053591A1 (de) 1999-03-08 2000-09-14 Bayer Aktiengesellschaft Thiazolylharnstoff-derivate und ihre verwendung als antivirale mittel
US6794412B1 (en) 1999-03-11 2004-09-21 Bristol-Myers Squibb Pharma Company Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
US6610846B1 (en) 1999-03-29 2003-08-26 Hoffman-La Roche Inc. Heteroaromatic glucokinase activators
SI1169312T1 (en) 1999-03-29 2005-02-28 F. Hoffmann-La Roche Ag Glucokinase activators
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US6503949B1 (en) 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
USRE40876E1 (en) 1999-06-21 2009-08-18 Eli Lilly And Company Method for treating non-insulin dependent diabetes using thiazolidinediones with glucagonlike peptide-1 and agonists thereof
BR0012068A (pt) 1999-06-30 2002-05-14 Daiichi Seiyaku Co Compostos inibidores de vla-4
US6114365A (en) 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
US6294546B1 (en) 1999-08-30 2001-09-25 The Broad Of Trustees Of The Leland Stanford Junior University Uses of diterpenoid triepoxides as an anti-proliferative agent
EP1211246B1 (en) 1999-09-09 2004-02-25 Kumiai Chemical Industry Co., Ltd. Pyrimidine derivatives and herbicides containing the same
US6353111B1 (en) 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
JP2003521543A (ja) 2000-02-07 2003-07-15 アボット ゲーエムベーハー ウント カンパニー カーゲー ２−ベンゾチアゾリル尿素誘導体およびそのプロテインキナーゼ阻害剤としての使用
US6608038B2 (en) 2000-03-15 2003-08-19 Novartis Ag Methods and compositions for treatment of diabetes and related conditions via gene therapy
AU2001252270B2 (en) 2000-05-03 2005-12-15 F. Hoffmann-La Roche Ag Hydantoin-containing glucokinase activators
KR100502033B1 (ko) 2000-05-03 2005-07-25 에프. 호프만-라 로슈 아게 알키닐 페닐 헤테로방향족 글루코키나제 활성제
KR100519826B1 (ko) 2000-05-08 2005-10-06 에프. 호프만-라 로슈 아게 파라-아민 치환된 페닐아미드 글루코키나제 활성화제
AU778036B2 (en) 2000-05-08 2004-11-11 F. Hoffmann-La Roche Ag Substituted phenylacetamides and their use as glucokinase activators
JP2004501191A (ja) 2000-06-28 2004-01-15 テバ　ファーマシューティカル　インダストリーズ　リミティド カルベジロール
MXPA03000365A (es) 2000-07-20 2003-05-27 Hoffmann La Roche Bencenacetamida substituida con alfa-acilo y alfa-heteroatomo como activadores de la glucocinasa.
US20020173507A1 (en) 2000-08-15 2002-11-21 Vincent Santora Urea compounds and methods of uses
US6645990B2 (en) 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
WO2002046173A1 (en) 2000-12-06 2002-06-13 F. Hoffmann-La Roche Ag Fused heteroaromatic glucokinase activators
WO2002060898A1 (en) 2001-01-31 2002-08-08 Pfizer Products Inc. Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
EP1256578B1 (en) 2001-05-11 2006-01-11 Pfizer Products Inc. Thiazole derivatives and their use as cdk inhibitors
JP2004536845A (ja) 2001-07-11 2004-12-09 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド サイトカイン媒介疾患の治療方法
US6881746B2 (en) 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
WO2003055482A1 (en) 2001-12-21 2003-07-10 Novo Nordisk A/S Amide derivatives as gk activators
EP1321463B1 (en) 2001-12-21 2007-08-08 Virochem Pharma Inc. Thiazole derivatives and their use for the treatment or prevention of Flavivirus infections
BR0312023A (pt) 2002-06-27 2005-03-22 Novo Nordisk As Composto, composto ativador da glicose cinase, método para evitar a hipoglicemia, uso de um composto, e, composição farmacêutica
NZ541824A (en) 2003-02-26 2010-04-30 Banyu Pharma Co Ltd Heteroarylcarbamoylbenzene derivatives as glucokinase activators
US7111188B2 (en) 2003-07-31 2006-09-19 International Business Machines Corporation Dynamically configurable fault tolerance in autonomic computing with multiple service points
TW200505894A (en) 2003-08-08 2005-02-16 Yamanouchi Pharma Co Ltd Tetrahydro-2H-thiopyran-4-carboxamide derivative
US7029649B2 (en) 2003-08-26 2006-04-18 General Motors Corporation Combinations of hydrogen storage materials including amide/imide
AU2003269484A1 (en) 2003-09-11 2005-03-29 Biocon Limited Salt of atorvastatin with metformin
JP4834840B2 (ja) 2004-01-06 2011-12-14 ノヴォ ノルディスク アー／エス ヘテロアリール尿素およびグルコキナーゼ活性化剤としてのその使用
CN1922664A (zh) 2004-02-26 2007-02-28 皇家飞利浦电子股份有限公司 用于电子书应用的多螺旋混合盘
JP4334374B2 (ja) 2004-03-05 2009-09-30 株式会社東芝 被ばく線量評価方法、被ばく線量評価システムおよび被ばく線量評価プログラム
KR20070002081A (ko) 2004-04-02 2007-01-04 버텍스 파마슈티칼스 인코포레이티드 Ｒｏｃｋ 및 기타 단백질 키나아제의 억제제로서 유용한아자인돌
JP2008502658A (ja) * 2004-06-17 2008-01-31 ノボ　ノルディスク　アクティーゼルスカブ 肝臓選択的グルコキナーゼ活性化因子の使用
CA2582567A1 (en) 2004-10-07 2006-04-13 Stem Cell Therapeutics Corp. Stimulation of proliferation of pluripotential stem cells through administration of pregnancy associated compounds
US20060246141A1 (en) 2005-04-12 2006-11-02 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
US20100028439A1 (en) 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
ES2382815T3 (es) 2005-07-08 2012-06-13 Novo Nordisk A/S Dicicloalquilcarbamoil ureas como activadores de glucoquinasa
US7582769B2 (en) 2005-07-08 2009-09-01 Novo Nordisk A/S Dicycloalkyl urea glucokinase activators
US7884210B2 (en) 2005-07-14 2011-02-08 Novo Nordisk A/S Ureido-thiazole glucokinase activators
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
WO2008084043A1 (en) 2007-01-09 2008-07-17 Novo Nordisk A/S Urea glucokinase activators
WO2008084044A1 (en) 2007-01-11 2008-07-17 Novo Nordisk A/S Urea glucokinase activators
JPWO2009054251A1 (ja) 2007-10-25 2011-03-03 三洋電機株式会社 発電装置
BRPI0912802A2 (pt) 2008-05-16 2015-10-13 Takeda San Diego Inc ativadores de glicoquinase
WO2009140824A1 (en) 2008-05-22 2009-11-26 Yuvad Technologies Co., Ltd. A system for identifying motion video/audio content
WO2010107610A1 (en) 2009-03-17 2010-09-23 Merck Sharp & Dohme Corp. Method for treatment of diabetes and related conditions with combination therapy and compositions containing such compounds
EP2419097B1 (en) 2009-04-16 2013-09-25 Taisho Pharmaceutical Co., Ltd. Pharmaceutical composition comprising (1s)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-d-glucitol and metformin and uses thereof in the treatment of diabetes
WO2011025270A2 (ko) 2009-08-25 2011-03-03 한올바이오파마주식회사 메트포르민 카페익산염, 그의 제조방법, 그를 포함하는 약학조성물 및 그를 포함하는 복합제제
PT2576524T (pt) 2010-05-26 2017-11-17 Vtv Therapeutics Llc Resumo
EP2392575A1 (en) 2010-06-04 2011-12-07 LEK Pharmaceuticals d.d. A novel synthetic approach to ß-aminobutyryl substituted compounds
JP6016621B2 (ja) 2012-12-26 2016-10-26 花王株式会社 清掃具のジョイント構造
CN105188676A (zh) 2013-03-04 2015-12-23 Vtv治疗有限责任公司 包括葡糖激酶活化剂的固体组合物及其制备和使用方法
HK1213780A1 (zh) 2013-03-04 2016-07-15 Vtv治疗有限责任公司 穩定的葡萄糖激酶活化劑組合物
JP6102611B2 (ja) 2013-07-31 2017-03-29 セイコーエプソン株式会社 液体噴射装置及びワイピング方法
US10696424B2 (en) 2016-06-29 2020-06-30 Lockheed Martin Corporation Spacecraft structures incorporating graphene and operation thereof
RU2728824C1 (ru) 2016-12-15 2020-07-31 Хуа Медсин (Шанхай) Лтд. Препарат активатора глюкокиназы для перорального введения и способ его получения
CN112040945A (zh) 2018-06-12 2020-12-04 Vtv治疗有限责任公司 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
CN116056760A (zh) 2020-06-08 2023-05-02 维特卫治疗有限责任公司 {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的结晶形式及其用途
CA3181722A1 (en) 2020-06-08 2021-12-16 Jing TENG Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104349790A (zh) * 2012-05-17 2015-02-11 转化技术制药有限责任公司 用于治疗糖尿病的葡萄糖激酶活化剂组合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JEFFREY A PFEFFERKORN等: "Strategies for the design of hepatoselective glucokinase activators to treat type 2 diabetes", EXPERT OPINION ON DRUG DISCOVERY, vol. 8, no. 3, pages 319 - 330, XP002794760, DOI: 10.1517/17460441.2013.748744 *
MARK F. MCCARTY: "In type 1 diabetics, high-dose biotin may compensate for low hepatic insulin exposure, promoting a more normal expression of glycolytic and gluconeogenic enyzymes and thereby aiding glycemic control", MEDICAL HYPOTHESES, vol. 95, no. 10, pages 45 - 48, XP029751724, DOI: 10.1016/j.mehy.2016.08.002 *

Also Published As

Publication number Publication date
AU2019287437A1 (en) 2020-09-10
KR20210020866A (ko) 2021-02-24
JP2021526130A (ja) 2021-09-30
CN120131969A (zh) 2025-06-13
US20210169857A1 (en) 2021-06-10
MX2024004333A (es) 2024-04-23
US20200147052A1 (en) 2020-05-14
US20240245656A1 (en) 2024-07-25
CA3093025A1 (en) 2019-12-19
US10952993B2 (en) 2021-03-23
AU2025203014A9 (en) 2026-03-05
US20210169858A1 (en) 2021-06-10
EP3806852A1 (en) 2021-04-21
AU2025203014A1 (en) 2025-05-15
JP2024150496A (ja) 2024-10-23
EP4487909A2 (en) 2025-01-08
MX2020008905A (es) 2020-12-03
WO2019241089A1 (en) 2019-12-19
US11833136B2 (en) 2023-12-05
EP4487909A3 (en) 2025-03-19
CN121371187A (zh) 2026-01-23
US11974989B2 (en) 2024-05-07

Similar Documents

Publication Publication Date Title
Chan et al. Pharmacological management of type 2 diabetes mellitus: rationale for rational use of insulin
US20240245656A1 (en) Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
Codario Type 2 diabetes, pre-diabetes, and the metabolic syndrome: the primary care guide to diagnosis and management
Senior et al. Fast-acting insulin aspart and the need for new mealtime insulin analogues in adults with type 1 and type 2 diabetes: a Canadian perspective
RU2705797C2 (ru) Лечение сахарного диабета с помощью составов инсулинов длительного действия
Lebovitz Treating hyperglycemia in type 2 diabetes: new goals and strategies
CN108079281A (zh) 用于2型糖尿病患者中的血糖控制的药物组合
KR20260036616A (ko) Glp1r 작용제의 치료적 용도
Skugor Medical treatment of diabetes mellitus
Manu et al. Pharmacological management of diabetes mellitus: a century of expert opinions in cecil textbook of medicine
JP2021526130A5 (https=)
Gentile et al. Lispro insulin in people with non-alcoholic liver cirrhosis and type 2 diabetes mellitus
Cabré et al. From Current Therapeutics to Multitarget Ligands: A Review of Diabetes Pharmacological Treatments
Yuan et al. Safety and efficacy of sitagliptin in combination with transient continuous subcutaneous insulin infusion (CSII) therapy in patients with newly diagnosed type 2 diabetes
KR20070029276A (ko) 인슐린으로 인한 저혈당증을 예방하고 조절하기 위한조성물 및 방법
HK40042198A (en) Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
Ithape et al. A review on pharmacotherapy of diabetes mellitus
DOĞANTEKIN et al. TYPE 2 DIABETES MELLITUS
Kapellen Pharmacotherapy of children and adolescents with type 1 diabetes mellitus
JPWO2019241089A5 (https=)
Quinn Pharmacologic management of the patient with type 2 diabetes
Matthaei et al. Medical antihyperglycaemic treatment of diabetes mellitus type 2
Nicholson Drugs used in diabetes mellitus
Jyoti A Study on the Influence of Rifampicin and Ranitidine on the Pharmacodynamics and Pharmacokinetics of Vildagliptin in Rats and Rabbits
Florez et al. 21| Oral Agents and Insulin in Care of

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40042198

Country of ref document: HK